Supplement Marketers Settle Attention Deficit Disorder Claims With FTC
This article was originally published in The Tan Sheet
Executive Summary
Dietary supplement marketers Efamol Nutraceuticals and J&R Research have agreed to settle Federal Trade Commission charges that claims made for their products to treat attention deficit/hyperactivity disorder and other conditions and diseases are unsubstantiated.